Projecting risk for metastasis after radical prostatectomy

A new paper in Clinical Genitourinary Cancer has provided us with some more detailed information about risk for metastasis in men with recurrent prostate cancer after first-line surgery. … READ MORE …

BPH, 5-ARIs, PSA, and risk for prostate cancer diagnosis

It will come as no surprise to the well-informed that if you are taking a 5-alpha-reductase inhibitor (a 5-ARI) like dutasteride or finasteride for benign prostatic hyperplasia (BPH), it significantly lowers your “normal” PSA level (to about half the actual value). … READ MORE …

FDA approves new type of PSA testing methodology

According to a report on the US Food and Drug Administration (FDA) web site, the FDA has just approved the “finger-prick” Sangia Total PSA blood test developed by OPKO Diagnostics. … READ MORE …

Good news and less good news for OPKO Diagnostics

So first the “less good” news … READ MORE …

Can MRI data improve decision-making about the need for a biopsy?

Last week we noted that adding MRI data to the Partin tables and to the Kattan/MSKCC nomograms did not seem to improve the accuracy of prognosis of outcomes after radical prostatectomy. … READ MORE …

Back to basics: two useful articles to pass along

The Prostate Cancer Foundation posted two useful and basic articles on its blog site this December that may be useful resources for men concerned about their risk for or newly diagnosed with prostate cancer or monitoring their PSA over time (for any one of all sorts of possible reasons). … READ MORE …

Prediction of risk for aggressive prostate cancer among Black males

A newly published paper has now suggested that data from a single PSA test carried out when the men are between 40 and 64 years of age can be used to project risk for aggressive prostate cancer among African-American men. … READ MORE …